Heart Failure With Preserved Ejection Fraction Clinical Trials 2023

What Are Heart Failure With Preserved Ejection Fraction Clinical Trials?

Heart failure with preserved ejection fraction is found in half of the patients diagnosed with heart failure. Diagnosing this condition can be challenging, and treatments can ease symptoms but don't offer patients a better life expectancy rate.

Based on current research, heart failure with preserved ejection fraction occurs when other chronic conditions damage the heart. A few conditions that can lead to this are obesity, diabetes, coronary artery disease, and anemia.

Clinical trials for heart failure with preserved ejection fraction aim to diagnose this condition early and find new treatments to help extend the longevity of patients diagnosed. Most patients diagnosed with this condition have a life expectancy of 2.1 years to 5 years once diagnosed.

Why Is Heart Failure With Preserved Ejection Fraction Studied Through Clinical Trials?

Heart failure with preserved ejection fraction is being studied through clinical trials because there is a lack of treatment for this condition. Those diagnosed with this condition increase by 1% yearly. While this is known as a condition that affects the elderly, in recent years, most patients diagnosed are under the age of 65.

At present, no existing treatments have been able to increase the mortality rate of those diagnosed with heart failure with preserved ejection fraction. Therefore, clinical trials for this condition hope to establish new methods of effective treatments in managing heart failure with preserved ejection fraction and increasing a patient’s life expectancy.

What Are The Types Of Treatments Available For Heart Failure With Preserved Ejection Fraction?

Heart failure with preserved ejection fraction is treated in many ways depending on the severity of the condition. Here are the most common treatments:

1. Diuretics. Diuretics may be prescribed to reduce cardiac filling pressure and to minimize the symptoms associated with heart failure with preserved ejection fraction.
2. Medications. Medications for this condition include calcium channel blockers, beta-blockers, ACEIs, ARBs, and digoxin.
3. Cellular cyclic guanosine monophosphate signaling. This type of treatment is still in the research phase but includes nitrate oxide donors, natriuretic peptides, soluble guanylate cyclase activators, and stimulators and therapies targeting energy myocardial substrate utilization.
4. Dietary sodium and fluid restriction. Dietary sodium and fluid restriction is usually implemented in those with congestive cardiac failure, and this type of treatment replaces the need for diuretics.

One of the most current clinical treatments for heart failure with preserved ejection fraction is dapagliflozin, a drug therapy used to help improve and control co-morbidities in patients with this condition.

What Are Some Recent Breakthrough Clinical Trials For Heart Failure With Preserved Ejection Fraction?

There have been numerous clinical trials on heart failure with preserved ejection fraction. However, many of them are still in the trial phases, and there haven't been too many revolutionary treatments to improve the mortality rate in patients. A few of the most interesting clinical trials are:

2021: Jardiance therapy for heart failure with preserved ejection fraction. The FDA has approved Jardiance as an investigational treatment for heart failure patients with preserved ejection fraction. Studies have shown that this treatment reduced cardiovascular death and hospitalizations by 21%.

2023: sacubitril/valsartan for treating heart failure patients with preserved ejection fraction. Patients who have received treatment with sacubitril/valsartan showed improvements of between 45% and 57%. This treatment, like Jardiance, has helped lessen hospitalizations and deaths in patients with this disease.

Who Are Some Of The Key Opinion Leaders / Researchers Conducting Heart Failure With Preserved Ejection Fraction Clinical Trial Research?

Stuart B. Prenner, MD, is a heart failure and transport cardiologist and works at the Perelman Center for advanced medicine. Prenner has 32 publications and is a specialist in heart failure with preserved ejection fraction. Dr. Prenner is also a part of the Heart Failure Society.

Parag Goyal, M.D., MSc, is an advanced heart failure physician and specializes in improving the lives of those diagnosed with heart failure conditions like heart failure with preserved ejection fraction. Dr. Goyal is also the founder of the Heart Failure with Preserved Ejection Fraction foundation.